Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma

Nicola Amodio, Maria Eugenia Gallo Cantafio, Cirino Botta, Valter Agosti, Cinzia Federico, Daniele Caracciolo, Domenica Ronchetti, Marco Rossi, Christoph Driessen, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derived as compared to healthy plasma cells, thus pointing to a tumor suppressor role in this malignancy. On this finding, we investigated miR-155 replacement as a potential anti-tumor strategy in MM. The miR-155 enforced expression triggered anti-proliferative and pro-apoptotic effects in vitro. Given the lower miR-155 levels in bortezomib-resistant as compared to sensitive MM cells, we analyzed the possible involvement of miR-155 in bortezomib resistance. Importantly, miR-155 replacement enhanced bortezomib anti-tumor activity both in vitro and in vivo in a xenograft model of human MM. In primary MM cells, we observed an inverse correlation between miR-155 and the mRNA encoding the proteasome subunit gene PSMβ5, whose dysregulation has been largely implicated in bortezomib resistance, and we validated PSMβ5 30UTR mRNA targeting, along with reduced proteasome activity, by miR-155. Collectively, our findings demonstrate that miR-155 elicits anti-MM activity, likely via proteasome inhibition, providing the framework for miR-155-based anti-MM therapeutic strategies.

Original languageEnglish
Article number236
JournalCancers
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Multiple Myeloma
Neoplasms
Proteasome Endopeptidase Complex
Bortezomib
Messenger RNA
Plasma Cells
MicroRNAs
Heterografts
Down-Regulation
Therapeutics
Genes

Keywords

  • Bortezomib
  • microRNA
  • miR-155
  • miRNA
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Amodio, N., Cantafio, M. E. G., Botta, C., Agosti, V., Federico, C., Caracciolo, D., ... Tassone, P. (2019). Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma. Cancers, 11(2), [236]. https://doi.org/10.3390/cancers11020236

Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma. / Amodio, Nicola; Cantafio, Maria Eugenia Gallo; Botta, Cirino; Agosti, Valter; Federico, Cinzia; Caracciolo, Daniele; Ronchetti, Domenica; Rossi, Marco; Driessen, Christoph; Neri, Antonino; Tagliaferri, Pierosandro; Tassone, Pierfrancesco.

In: Cancers, Vol. 11, No. 2, 236, 01.02.2019.

Research output: Contribution to journalArticle

Amodio, N, Cantafio, MEG, Botta, C, Agosti, V, Federico, C, Caracciolo, D, Ronchetti, D, Rossi, M, Driessen, C, Neri, A, Tagliaferri, P & Tassone, P 2019, 'Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma', Cancers, vol. 11, no. 2, 236. https://doi.org/10.3390/cancers11020236
Amodio, Nicola ; Cantafio, Maria Eugenia Gallo ; Botta, Cirino ; Agosti, Valter ; Federico, Cinzia ; Caracciolo, Daniele ; Ronchetti, Domenica ; Rossi, Marco ; Driessen, Christoph ; Neri, Antonino ; Tagliaferri, Pierosandro ; Tassone, Pierfrancesco. / Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma. In: Cancers. 2019 ; Vol. 11, No. 2.
@article{e810547f0f264d15a162f09cc10f3bb8,
title = "Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma",
abstract = "Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derived as compared to healthy plasma cells, thus pointing to a tumor suppressor role in this malignancy. On this finding, we investigated miR-155 replacement as a potential anti-tumor strategy in MM. The miR-155 enforced expression triggered anti-proliferative and pro-apoptotic effects in vitro. Given the lower miR-155 levels in bortezomib-resistant as compared to sensitive MM cells, we analyzed the possible involvement of miR-155 in bortezomib resistance. Importantly, miR-155 replacement enhanced bortezomib anti-tumor activity both in vitro and in vivo in a xenograft model of human MM. In primary MM cells, we observed an inverse correlation between miR-155 and the mRNA encoding the proteasome subunit gene PSMβ5, whose dysregulation has been largely implicated in bortezomib resistance, and we validated PSMβ5 30UTR mRNA targeting, along with reduced proteasome activity, by miR-155. Collectively, our findings demonstrate that miR-155 elicits anti-MM activity, likely via proteasome inhibition, providing the framework for miR-155-based anti-MM therapeutic strategies.",
keywords = "Bortezomib, microRNA, miR-155, miRNA, Multiple myeloma",
author = "Nicola Amodio and Cantafio, {Maria Eugenia Gallo} and Cirino Botta and Valter Agosti and Cinzia Federico and Daniele Caracciolo and Domenica Ronchetti and Marco Rossi and Christoph Driessen and Antonino Neri and Pierosandro Tagliaferri and Pierfrancesco Tassone",
year = "2019",
month = "2",
day = "1",
doi = "10.3390/cancers11020236",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "2",

}

TY - JOUR

T1 - Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma

AU - Amodio, Nicola

AU - Cantafio, Maria Eugenia Gallo

AU - Botta, Cirino

AU - Agosti, Valter

AU - Federico, Cinzia

AU - Caracciolo, Daniele

AU - Ronchetti, Domenica

AU - Rossi, Marco

AU - Driessen, Christoph

AU - Neri, Antonino

AU - Tagliaferri, Pierosandro

AU - Tassone, Pierfrancesco

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derived as compared to healthy plasma cells, thus pointing to a tumor suppressor role in this malignancy. On this finding, we investigated miR-155 replacement as a potential anti-tumor strategy in MM. The miR-155 enforced expression triggered anti-proliferative and pro-apoptotic effects in vitro. Given the lower miR-155 levels in bortezomib-resistant as compared to sensitive MM cells, we analyzed the possible involvement of miR-155 in bortezomib resistance. Importantly, miR-155 replacement enhanced bortezomib anti-tumor activity both in vitro and in vivo in a xenograft model of human MM. In primary MM cells, we observed an inverse correlation between miR-155 and the mRNA encoding the proteasome subunit gene PSMβ5, whose dysregulation has been largely implicated in bortezomib resistance, and we validated PSMβ5 30UTR mRNA targeting, along with reduced proteasome activity, by miR-155. Collectively, our findings demonstrate that miR-155 elicits anti-MM activity, likely via proteasome inhibition, providing the framework for miR-155-based anti-MM therapeutic strategies.

AB - Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derived as compared to healthy plasma cells, thus pointing to a tumor suppressor role in this malignancy. On this finding, we investigated miR-155 replacement as a potential anti-tumor strategy in MM. The miR-155 enforced expression triggered anti-proliferative and pro-apoptotic effects in vitro. Given the lower miR-155 levels in bortezomib-resistant as compared to sensitive MM cells, we analyzed the possible involvement of miR-155 in bortezomib resistance. Importantly, miR-155 replacement enhanced bortezomib anti-tumor activity both in vitro and in vivo in a xenograft model of human MM. In primary MM cells, we observed an inverse correlation between miR-155 and the mRNA encoding the proteasome subunit gene PSMβ5, whose dysregulation has been largely implicated in bortezomib resistance, and we validated PSMβ5 30UTR mRNA targeting, along with reduced proteasome activity, by miR-155. Collectively, our findings demonstrate that miR-155 elicits anti-MM activity, likely via proteasome inhibition, providing the framework for miR-155-based anti-MM therapeutic strategies.

KW - Bortezomib

KW - microRNA

KW - miR-155

KW - miRNA

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85063586909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063586909&partnerID=8YFLogxK

U2 - 10.3390/cancers11020236

DO - 10.3390/cancers11020236

M3 - Article

AN - SCOPUS:85063586909

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

M1 - 236

ER -